News Articles

Ferring and the Chinese Academy of Sciences Collaborate to Advance Research in Reproductive Medicine SAINT-PREX, Switzerland -Thursday, January 11th 2018 [ar]  

(BUSINESS WIRE) -- Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) today announced a long-term collaboration to advance basic and translational research in reproductive medicine through the development of novel product candidates and therapeutic strategies. As part of the...

Ferring Receives Swiss Approval For Rekovelle®, The First Personalised Fertility Treatment Using an... SAINT-PREX, Switzerland -Monday, November 27th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in...

Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector... SAINT-PREX, Switzerland -Tuesday, October 10th 2017

Ferring enters agreement with Antares Pharma Inc. for worldwide rights to ZomaJet™ needle-free injector device ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), indicated to treat Growth Hormone Deficiency in children and Turner Syndrome in girls ZomaJet helps increase...

Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer SAINT-PREX, Switzerland -Tuesday, October 3rd 2017

(BUSINESS WIRE) -- Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately. He will be responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance. In addition, he will...

Ferring Appoints Lars Peter Brunse to Executive Board SAINT-PREX, Switzerland -Monday, July 3rd 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective immediately. Lars Peter Brunse joined Ferring as Associate Director Technical...

Ferring Appoints Aaron Graff to Executive Board SAINT-PREX, Switzerland -Thursday, June 1st 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive Board, effective immediately. Aaron Graff joined Ferring in 2002 as Vice President Global...

World Bedwetting Day Steering Committee: New global guidelines call for more effective treatment for bedwetting, a... SAINT-PREX, Switzerland -Tuesday, May 30th 2017 [ar]  

Bedwetting affects 1 in 15 seven year olds1 Boys are twice as likely to suffer as girls and the risk is 44% if one parent wet the bed and 77% if both did, suggesting a genetic link2 Bedwetting has a serious impact on self-esteem, emotional well-being, functioning and school/work...

Ferring Announces Exclusive Agreement with Alrise Biosystems for the Development of an Injectable, Controlled-Release... SAINT-PREX, Switzerland -Monday, April 10th 2017

(BUSINESS WIRE) -- Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alrise’s ImSus® Technology Platform for the development of an injectable, controlled-release...

Ferring Highlights Progress on Social and Environmental Goals in Corporate Social Responsibility (CSR) Review 2015-2016 ... SAINT-PREX, Switzerland -Thursday, April 6th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals in 2015 and 2016 across four key pillars for focus and activity: People, Business Ethics, Environment and Community. "We have...

Ferring Appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer SAINT-PREX, Switzerland -Monday, April 3rd 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective 1st July 2017. Moorhead succeeds Peter Wilden, who joined Ferring 25 years ago and was one of the original members of the Group...

Ferring Pharmaceuticals: Waking up to Go to the Toilet is the Number One Cause of a Poor Night’s Sleep, Say... SAINT PREX, Switzerland -Friday, March 17th 2017 [ar] [fr]

Nocturia, the need to wake up and urinate more than once at night, disturbs the sleep of 1 in 3 adults over the age of 30 and two thirds of adults over the age of 651 Up to 80% of people who complain of a disturbed night’s sleep report that nocturia is the main reason they wake in the...

Ferring collaborates with ICF on development of a potential new treatment for anal fissures with a focus on improving... SAINT-PREX, Switzerland -Wednesday, March 15th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research collaboration aimed at developing a mucoadhesive rectal delivery system to treat anal fissures and to improve quality of care for patients with inflammatory bowel...

Ferring Announces Recipients of Innovation Grants Program 2016-2017 SAINT-PREX, Switzerland -Wednesday, February 15th 2017

(BUSINESS WIRE)-- Ferring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute (FRI) which provides grants of up to $100,000 for early stage research. The program focuses on novel extracellular drug targets...

Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement SAINT-PREX, Switzerland -Monday, February 13th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary and unique Stabilized Injectable Formulation platform (SIF)...

Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based... SAINT-PREX, Switzerland -Monday, January 30th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced today that the companies have entered into a license agreement and initiated an early development agreement to leverage Enteris’ proprietary and patented oral peptide and small molecule delivery platform,...

Ferring Partners with Intralytix to Develop Bacteriophage Treatments for Conditions Associated with the Microbiome and... SAINT-PREX, Switzerland -Monday, January 9th 2017

(BUSINESS WIRE)-- Ferring Pharmaceuticals is partnering with Intralytix, Inc to develop and commercialise bacteriophage-based treatments for conditions associated with the presence of pathogenic bacteria or dysbiosis of the microbiome. The human body is host to trillions of microbes,...

Ferring and IMAB Sign Licensing Agreement Granting IMAB Exclusive Rights in Asia to Olamkicept for the Treatment of... SAINT-PREX, Switzerland -Monday, December 19th 2016

(BUSINESS WIRE)-- Ferring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights to olamkicept (pINN) in Asia. Olamkicept is a new recombinant protein inhibitor of the interleukin-6 pathway. Interleukin-6 is associated with...

Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos Collaborate on Nanotechnology R&D... SAINT-PREX, Switzerland -Wednesday, November 30th 2016

(BUSINESS WIRE)-- Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving the bioavailability, efficacy and safety profile of oral therapeutic medicines through nanotechnology. Potential benefits of research in this area include...

Ferring Pharmaceuticals: Wake up to Nocturia: the Most Common Cause of Disrupted Sleep That Could Be Damaging Your... SAINT PREX, Switzerland -Sunday, March 20th 2016 [ar] [fr]

Nocturia is the frequent need to pass water during the night1 Nocturia is the most common cause of sleep disturbance2 Up to 80% of people who complain of a disturbed night’s sleep report that nocturia is the main reason they wake in the middle of the night.3 By not recognising the...

Ferring announces the start of the PRONOUNCE Trial for patients with advanced prostate cancer and cardiovascular disease... SAINT PREX, Switzerland -Tuesday, February 9th 2016 [ar] [fr]

(BUSINESS WIRE)-- Ferring Pharmaceuticals announced today the commencement of the Phase 3b PRONOUNCE Trial. The trial will compare the occurrence of major adverse cardiovascular events (MACEs) in patients with prostate cancer and cardiovascular disease (CVD), receiving the GnRH receptor...

Results 1-20 of 20